Sionna Therapeutics (NASDAQ:SION) Cut to Neutral at Guggenheim

Guggenheim downgraded shares of Sionna Therapeutics (NASDAQ:SION) from a buy rating to a neutral rating in a research report released on Monday, MarketBeat reports.

A number of other equities research analysts have also weighed in on SION. Citigroup lowered Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday. Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 target price for the company in a research report on Monday. Citizens Jmp lowered Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $7.00 price objective on shares of Sionna Therapeutics in a research note on Monday. One analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $42.22.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $6.25 on Monday. The company’s 50 day moving average price is $40.38 and its two-hundred day moving average price is $39.67. The firm has a market capitalization of $282.56 million, a P/E ratio of -2.87 and a beta of 1.33. Sionna Therapeutics has a fifty-two week low of $4.01 and a fifty-two week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, analysts expect that Sionna Therapeutics will post -2.65 earnings per share for the current year.

Insider Buying and Selling at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director directly owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 403,726 shares of company stock worth $18,259,354. 5.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sionna Therapeutics

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Sionna Therapeutics in the second quarter worth approximately $64,875,000. Eventide Asset Management LLC acquired a new stake in Sionna Therapeutics during the 4th quarter valued at approximately $26,290,000. Vanguard Group Inc. raised its holdings in Sionna Therapeutics by 81.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after purchasing an additional 512,803 shares during the last quarter. State Street Corp raised its holdings in Sionna Therapeutics by 188.7% during the 4th quarter. State Street Corp now owns 693,395 shares of the company’s stock worth $28,526,000 after purchasing an additional 453,196 shares during the last quarter. Finally, Jennison Associates LLC lifted its position in shares of Sionna Therapeutics by 30.1% in the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares during the period.

Sionna Therapeutics News Summary

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The stock’s rebound may reflect bargain hunting and short-term volatility following the steep selloff, although no new positive clinical data were reported.
• Neutral Sentiment: Analyst opinion has broadly converged around a more cautious stance. Royal Bank of Canada upgraded SION to “Sector Perform,” while Stifel Nicolaus assigned a “Hold” rating. Royal Bank of Canada upgrade
• Negative Sentiment: Sionna reported that its Phase 2a PreciSION CF trial of lead candidate SION-719 failed to achieve its key endpoint for sweat-chloride reduction. The drug will not advance as an add-on therapy, severely damaging the company’s near-term cystic-fibrosis development prospects. Sionna halts lead cystic fibrosis drug
• Negative Sentiment: The clinical failure erased roughly 90% of SION’s market value and removed a potential competitive threat to Vertex Pharmaceuticals, whose shares benefited from the news. Vertex rises as Sionna trial fails
• Negative Sentiment: Several firms reduced their ratings, including Lifesci Capital and JonesTrading to “Hold,” Wedbush to “Neutral,” Raymond James to “Market Perform,” and BTIG and Guggenheim to lower ratings. These actions signal reduced confidence after the trial result. Wedbush downgrade
• Negative Sentiment: Levi & Korsinsky announced a pending investor investigation into potential securities-law violations related to disclosures that allegedly indicated SION-719 was on track before the failed trial outcome. The investigation adds legal and reputational risk. Sionna investor investigation notice

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.